An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma

J Biol Response Mod. 1985 Dec;4(6):664-8.

Abstract

Sixteen patients with metastatic malignant melanoma were treated with poly(I,C)-LC 5 mg/m2 twice weekly by intravenous injection. No antitumor responses occurred. Fever (frequently greater than 40 degrees C) and fatigue were dose limiting toxicities. One patient developed a fever of 42.2 degrees C when poly(I,C)-LC was given on 2 consecutive days. Interferon was consistently detected in the serum 8 h after a single injection of poly(I,C)-LC (median titer 199 U/ml). No enhancement of interferon induction was detected on the second day when poly(I,C)-LC was given on 2 consecutive days.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity
  • Carboxymethylcellulose Sodium / administration & dosage
  • Carboxymethylcellulose Sodium / therapeutic use*
  • Carboxymethylcellulose Sodium / toxicity
  • Drug Evaluation
  • Fatigue / chemically induced
  • Female
  • Fever / chemically induced
  • Humans
  • Interferons / blood
  • Male
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / secondary
  • Methylcellulose / analogs & derivatives*
  • Middle Aged
  • Poly I-C / administration & dosage
  • Poly I-C / therapeutic use*
  • Poly I-C / toxicity
  • Polylysine / administration & dosage
  • Polylysine / therapeutic use*
  • Polylysine / toxicity

Substances

  • Antineoplastic Agents
  • Polylysine
  • poly ICLC
  • Methylcellulose
  • Interferons
  • Carboxymethylcellulose Sodium
  • Poly I-C